EP3498266A1 — Formulations of copanlisib
Assigned to Bayer Consumer Care AG · Expires 2019-06-19 · 7y expired
What this patent protects
The present invention relates to : • a method of preparing a stable, copanlisib-containing aqueous bulk solution suitable for lyophilisation and for therapeutic applications ; • a stable, copanlisib-containing bulk solution, of increased solubility which is directly suitable fo…
USPTO Abstract
The present invention relates to : • a method of preparing a stable, copanlisib-containing aqueous bulk solution suitable for lyophilisation and for therapeutic applications ; • a stable, copanlisib-containing bulk solution, of increased solubility which is directly suitable for lyophilisation ; • a method of lyophilizing such a copanlisib-containing aqueous bulk solution ; • a stable, lyophilized, copanlisib-containing solid, in particular powder or cake, particularly containing a therapeutic dose of copanlisib in one or two containers, particularly one sealed container; • a method of reconstituting such lyophilisates ; and • a stable, reconstituted, copanlisib-containing solution of increased solubility, suitable for further dilution and for therapeutic applications.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.